Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison

Hepatology

Volumn 26, Issue 6, 1997, Pages 1640-1645

  Tong, Myron J ^a   Blatt, Lawrence M ^b   Mchutchison, John G ^b   Co, Ruth L ^b   Conrad, Andrew ^b  

^a HUNTINGTON MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030695103     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260637     Document Type: Article

References (27)

1. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
2. Tong MJ, Lee SY, Hywang SJ, Co RL, Lai PP, Chien D, Kuo G. Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma. West J Med 1994;160:133-138.
3. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
4. Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United States: recipient characteristics and outcome. In: Terasaki PI, Cecka JM, eds. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995:19-33.
5. Hoofnagle JH, Mullen KD, Jones DB, Rustigi V, DiBisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alfa Interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
6. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant Interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
7. Marcellin P, Boyer N, Giostra E, Degott C, Courcouce AM, Degos F, Coppere H, Cales P, et al. Recombinant human (alpha) interferon in patients with chronic non-A and non-B hepatitis: a multicenter randomized controlled trial from France. HEPATOLOGY 1991;13:393-397.
8. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud J-P, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
9. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
10. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, et al. Clinical predictors of response to recombinant interferon alpha treatment in patients with chronic non-A non-B hepatitis (hepatitis C). J Viral Hepatitis 1994;1:55-63.
11. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to Interferon in patients with chronic hepatitis C. J Hepatol 1994;21:12-17.
12. Martinot-Peignoux M, Narcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main independent prognostic factors of sustained response to Interferon alfa therapy in chronic hepatitis C. HEPATOLOGY 1995;221:1050-1056.
13. Yamada G, Takatani M, Kishi F, Takahashi M, Toshihiko D, Tsuji T, Shin S, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. HEPATOLOGY 1995;22:1351-1354.
14. Stuyver L, Rossau R, Wyscur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1003;74:1093-1102.
15. Simmonds P, Alberti P, Alter J II, Bonino F, Bradley DW, Brechet C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. HEPATOLOGY 1994;19:1321-1324.
16. Tong MJ, Hwang SJ, Lefkowitch M, Lee SD, Co RL, Conrad A, Schmid, Lo KJ. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994;9:587-591.
17. Friis RH, Stellers TA. Epidemiology for public health practice. Gaithersburg, MD: Aspen, 1996.
18. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon alpha in chronic hepatitis C. Lancet 1993;342:1208-1209.
19. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, Donada C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon alpha in chronic hepatitis C. Ann Intern Med 1996;124:1058-1060.
20. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996;24:778-789.
21. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. HEPATOLOGY 1997;26:122S-127S.
22. McHutchison JG, Blatt LM, Russell J, Conrad A. Kinetics of changes in serum HCV RNA during interferon therapy in patients with chronic HCV infection [Abstract]. Gastroenterology 1997;112:A1330.
23. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ho cells in culture. HEPATOLOGY 1995;21:1003-10.
24. Castilla A, Prieto J, Fausto N. Transforming growth factors b1 and alpha in chronic liver disease. N Engl J Med 1991;324:993-40.
25. Ziol M, Van Nhieu JT, Roudot-Thorovol F, Metreau JM, Deugnier Y, Dhumeaux D, Zafrani ES. A histopathological study of the effects of 6-month versus 12-month interferon alpha 2b therapy in chronic hepatitis C. J Hepatol 1006;25:833-841.
26. Jensen D, Shafritz D, Craig JR, Krawitt E. Nonresponders to CIFN show clinically relevant improvements in liver histology [Abstract] Gastroenterology 1997;112:A1294.
27. Knodell RG, Kmal IG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.